Skip To Main Content

Logo Image

Juq 395 |verified| Now

| Model | Pathogen | Dosing Regimen | Outcome | |-------|----------|----------------|---------| | (immunocompetent CD‑1 mice) | MRSA (ATCC 43300) | 10 mg kg⁻¹ i.p., q12 h, 48 h | 4.8 log₁₀ CFU reduction vs. untreated; comparable to linezolid (5.1 log₁₀). | | Neutropenic thigh (Swiss albino mice) | Klebsiella pneumoniae (NDM‑1) | 20 mg kg⁻¹ p.o., q8 h, 24 h | 3.2 log₁₀ reduction; synergy with colistin (FIC = 0.5). | | Galleria mellonella infection model | Acinetobacter baumannii (carbapenem‑resistant) | 5 mg kg⁻¹ i.p., q12 h | 85 % survival at 72 h vs. 20 % in control. | | Pharmacokinetics (rat, oral) | — | 30 mg kg⁻¹ | C_max = 3.1 µg mL⁻¹; AUC₀‑∞ = 28 µg·h mL⁻¹; t₁/₂ ≈ 8 h. |

"The juq 395 is the latest innovation in the tech industry, designed to revolutionize the way we approach [specific area of interest]. This cutting-edge device boasts [list key features, such as advanced processing capabilities, sleek design, user-friendly interface, etc.]. What sets the juq 395 apart is its [unique feature or technology], making it a game-changer for [target audience or profession]." juq 395

: Crystallography (2.1 Å resolution) reveals that Juq‑395 occupies a pocket adjacent to the catalytic Cys115, inducing a conformational shift that blocks substrate access without covalently modifying the cysteine. This allosteric mechanism is distinct from fosfomycin, which covalently alkylates Cys115. | Model | Pathogen | Dosing Regimen |

The structural novelty of Juq‑395 lies in its within the quinazolinone core, which enables a tight, non‑covalent interaction with the active site of MurA (enolpyruvyl‑shikimate‑phosphate synthase). This binding mode circumvents the classic resistance mechanism—production of β‑lactamases—because the target enzyme is not a β‑lactam substrate. | | Galleria mellonella infection model | Acinetobacter

: Inhibition of MurA halts synthesis of the lipid‑II precursor, leading to rapid cell‑wall depletion and osmotic lysis. Time‑kill curves show a ≥ 3 log₁₀ CFU mL⁻¹ reduction within 4 h against MRSA, Enterococcus faecium (VRE), and carbapenem‑resistant Enterobacter cloacae .

: Surface plasmon resonance (SPR) studies demonstrate a K_D of 4 nM, with a slow dissociation rate (k_off ≈ 1 × 10⁻³ s⁻¹), indicating a tight, quasi‑irreversible interaction.

In the rapidly expanding landscape of antimicrobial research, has emerged in the last few years as a promising synthetic compound with a unique mode of action against multidrug‑resistant (MDR) bacteria. First reported in a 2022 patent filing by the biotech firm JuqBio Inc. , Juq‑395 is a small‑molecule inhibitor that targets the bacterial cell‑wall biosynthetic pathway in a manner distinct from existing β‑lactams, glycopeptides, and newer lipoglycopeptides. Because antimicrobial resistance (AMR) is now a leading global health threat—estimated to cause 10 million deaths per year by 2050—new agents such as Juq‑395 are of considerable scientific, clinical, and economic interest.

Logo Title

| Model | Pathogen | Dosing Regimen | Outcome | |-------|----------|----------------|---------| | (immunocompetent CD‑1 mice) | MRSA (ATCC 43300) | 10 mg kg⁻¹ i.p., q12 h, 48 h | 4.8 log₁₀ CFU reduction vs. untreated; comparable to linezolid (5.1 log₁₀). | | Neutropenic thigh (Swiss albino mice) | Klebsiella pneumoniae (NDM‑1) | 20 mg kg⁻¹ p.o., q8 h, 24 h | 3.2 log₁₀ reduction; synergy with colistin (FIC = 0.5). | | Galleria mellonella infection model | Acinetobacter baumannii (carbapenem‑resistant) | 5 mg kg⁻¹ i.p., q12 h | 85 % survival at 72 h vs. 20 % in control. | | Pharmacokinetics (rat, oral) | — | 30 mg kg⁻¹ | C_max = 3.1 µg mL⁻¹; AUC₀‑∞ = 28 µg·h mL⁻¹; t₁/₂ ≈ 8 h. |

"The juq 395 is the latest innovation in the tech industry, designed to revolutionize the way we approach [specific area of interest]. This cutting-edge device boasts [list key features, such as advanced processing capabilities, sleek design, user-friendly interface, etc.]. What sets the juq 395 apart is its [unique feature or technology], making it a game-changer for [target audience or profession]."

: Crystallography (2.1 Å resolution) reveals that Juq‑395 occupies a pocket adjacent to the catalytic Cys115, inducing a conformational shift that blocks substrate access without covalently modifying the cysteine. This allosteric mechanism is distinct from fosfomycin, which covalently alkylates Cys115.

The structural novelty of Juq‑395 lies in its within the quinazolinone core, which enables a tight, non‑covalent interaction with the active site of MurA (enolpyruvyl‑shikimate‑phosphate synthase). This binding mode circumvents the classic resistance mechanism—production of β‑lactamases—because the target enzyme is not a β‑lactam substrate.

: Inhibition of MurA halts synthesis of the lipid‑II precursor, leading to rapid cell‑wall depletion and osmotic lysis. Time‑kill curves show a ≥ 3 log₁₀ CFU mL⁻¹ reduction within 4 h against MRSA, Enterococcus faecium (VRE), and carbapenem‑resistant Enterobacter cloacae .

: Surface plasmon resonance (SPR) studies demonstrate a K_D of 4 nM, with a slow dissociation rate (k_off ≈ 1 × 10⁻³ s⁻¹), indicating a tight, quasi‑irreversible interaction.

In the rapidly expanding landscape of antimicrobial research, has emerged in the last few years as a promising synthetic compound with a unique mode of action against multidrug‑resistant (MDR) bacteria. First reported in a 2022 patent filing by the biotech firm JuqBio Inc. , Juq‑395 is a small‑molecule inhibitor that targets the bacterial cell‑wall biosynthetic pathway in a manner distinct from existing β‑lactams, glycopeptides, and newer lipoglycopeptides. Because antimicrobial resistance (AMR) is now a leading global health threat—estimated to cause 10 million deaths per year by 2050—new agents such as Juq‑395 are of considerable scientific, clinical, and economic interest.